The role of anti-tumor immunity triggered by CDK4/6 inhibitor has been previously reported by Goel et al.37 through activation of type III IFN response by increased intracellular levels of endogenous retroviral double-stranded RNA. This evidence concerns the gene CDK4 and neoplasm.